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ABSTRACT
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, which consists of the gp120 and gp41
subunits, is the focus of multiple strategies for vaccine development. Extensive Env glycosylation provides HIV-1 with protection
from the immune system, yet the glycans are also essential components of binding epitopes for numerous broadly neutralizing
antibodies. Recent studies have shown that when Env is isolated from virions, its glycosylation profile differs significantly from
that of soluble forms of Env (gp120 or gp140) predominantly used in vaccine discovery research. Here we show that exogenous
membrane-anchored Envs, which can be produced in large quantities in mammalian cells, also display a virion-like glycan pro-
file, where the glycoprotein is extensively decorated with high-mannose glycans. Additionally, because we characterized the gly-
cosylation with a high-fidelity profiling method, glycopeptide analysis, an unprecedented level of molecular detail regarding
membrane Env glycosylation and its heterogeneity is presented. Each glycosylation site was characterized individually, with
about 500 glycoforms characterized per Env protein. While many of the sites contain exclusively high-mannose glycans, others
retain complex glycans, resulting in a glycan profile that cannot currently be mimicked on soluble gp120 or gp140 preparations.
These site-level studies are important for understanding antibody-glycan interactions on native Env trimers. Additionally, we
report a newly observed O-linked glycosylation site, T606, and we show that the full O-linked glycosylation profile of membrane-
associated Env is similar to that of soluble gp140. These findings provide new insight into Env glycosylation and clarify key mo-
lecular-level differences between membrane-anchored Env and soluble gp140.
IMPORTANCE
A vaccine that protects against human immunodeficiency virus type 1 (HIV-1) infection should elicit antibodies that bind to the
surface envelope glycoproteins on the membrane of the virus. The envelope glycoproteins have an extensive coat of carbohy-
drates (glycans), some of which are recognized by virus-neutralizing antibodies and some of which protect the virus from neu-
tralizing antibodies. We found that the HIV-1 membrane envelope glycoproteins have a unique pattern of carbohydrates, with
many high-mannose glycans and also, in some places, complex glycans. This pattern was very different from the carbohydrate
profile seen for a more easily produced soluble version of the envelope glycoprotein. Our results provide a detailed characteriza-
tion of the glycans on the natural membrane envelope glycoproteins of HIV-1, a carbohydrate profile that would be desirable to
mimic with a vaccine.
Human immunodeficiency virus type 1 (HIV-1), the causativeagent of AIDS, currently infects more than 35 million people
globally (1–3). With no cure for the disease, the development of an
HIV-1 vaccine is a top public health priority. The HIV-1 envelope
glycoprotein (Env) spike is the only part of the virus accessible to
neutralizing antibodies; therefore, Env has been a target of intense
investigation as a vaccine immunogen (4, 5). Env is a trimer con-
sisting of three gp120 exterior glycoproteins and three gp41 trans-
membrane glycoproteins. The gp160 Env precursor is extensively
modified by high-mannose glycans, and after proteolytic matura-
tion, some of these are converted to complex carbohydrates. This
extensive degree of glycosylation, a feature of Env that contributes
to the biology of HIV-1 infection, is the focus of the current study.
More than half of the mass of Env is composed of glycans,
which contribute to viral biology in a number of ways (5, 6). They
are a prerequisite for the proper folding of Env, which is required
for protein function (7, 8). They also protect the protein from
detection by the immune system, by producing a “glycan shield”
(9, 10). As a result of the masking of underlying protein epitopes,
a very large portion of the protein is immunologically “silent,”
creating pathways for immune escape (11). In these two examples,
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the glycans can be viewed as amorphous masses that impact
protein structure and shield the protein surface from antibodies. If
these were the only roles of the glycans, one might conclude that
their presence is necessary but that the type of glycan occupying
each site is somewhat irrelevant.
Mounting evidence exists to show that the type of glycan pres-
ent on Env does, in fact, play a very significant role in the biological
properties and particularly in the immunogenicity of this protein.
For example, immunogenicity studies of the gp120 exterior Env
glycoprotein show that a decrease in the sialic acid content of the
glycans can increase the immunogenicity of the protein (12).
Other supporting work provides additional evidence that altered
glycosylation resulting from changes in the expression conditions
of the protein can impact the binding of gp120 to anti-HIV-1
antibodies from human sera (13). Additionally, in many in-
stances, a specific glycan is involved in the recognition of Env by
broadly neutralizing antibodies, and glycan specificity is necessary
for these antibodies to bind optimally. High-mannose glycans
have been shown to be critical to the binding of one of the first
broadly neutralizing antibodies identified, 2G12 (14). Since that
work, a number of other broadly neutralizing antibodies have also
been shown to contain specific types of glycans in their recogni-
tion elements (15–20). In fact, many of the antibodies that are of
great current interest contact a glycan as a component of their
epitope; these include antibodies PG9, PG16, PGT121, PGT125-
128, PGT130, PGT135, and CH01-04 (15–20). In sum, these stud-
ies demonstrate that the mere presence of glycosylation on Env is
not sufficient to guarantee faithful mimicry of the native Env
spike. Rather, the right types of glycans must be present in the
right places.
To capitalize on this realization, researchers have been working
to identify the glycosylation profile of the most native form of Env
that can be readily produced and analyzed. These studies have
been pioneered by Chris Scanlan and coworkers, who studied gly-
cosylation on virions produced from a variety of cell types (21,
22). Their results suggested that the Env glycosylation profile was
surprisingly simple, consisting almost exclusively of high-man-
nose glycans, and furthermore, that these glycans were present
irrespective of the type of cell producing the virus. We expand on
these seminal findings here, further asking the question: are high-
mannose glycans the most abundant glycoform at every site on
Env, or is glycan heterogeneity more complex when profiled on a
site-by-site basis? By conducting a site-by-site analysis of a pri-
mary HIV-1 Env trimer isolated from the plasma membranes of
CHO cells, we provide the first high-fidelity map of a native gly-
cosylation profile for Env. As demonstrated here, the glycosylation
profile of Env is not simply an entourage of high-mannose gly-
cans. Indeed, processed glycans predominate at particular sites.
These information-rich studies can immediately assist our under-
standing of native Env glycosylation and provide a foundation for
relating differences in glycosylation to differences in immunoge-
nicity between membrane-anchored and soluble forms of the pro-
tein.
MATERIALS AND METHODS
Reagents and materials. Trizma hydrochloride, Trizma base, urea, dithio-
threitol (DTT), tris(2-carboxyethyl)phosphine hydrochloride (TCEP), io-
doacetamide (IAM), ammonium hydroxide, citric acid, sodium citrate
trihydrate, and glacial acetic acid were purchased from Sigma (St. Louis,
MO). Other materials used in this study included Optima grade formic
acid and high-performance liquid chromatography (HPLC) grade aceto-
nitrile (Fisher Scientific), HPLC grade water (Honeywell Burdick and
Johnson), sequencing grade trypsin and chymotrypsin (Promega), glyc-
erol-free peptidyl-N-glycosidase F (PNGase F) cloned from Flavobacte-
rium meningosepticum (New England BioLabs), and endo--N-acetylglu-
cosaminidase H (Endo H) cloned from Streptomyces plicatus (EMD
Millipore). All reagents and buffers were prepared with deionized water
purified to at least 18 M with a Millipore Direct-Q 3 water purification
system.
Expression, solubilization, and purification of HIV-1 JR-FL mem-
brane-anchored Env trimers. For expression of the membrane-anchored
HIV-1 JR-FL Env()712 and Env()808 glycoproteins, the env cDNA
was codon-optimized and was cloned into an HIV-1-based lentiviral vec-
tor. These Env sequences comprised a heterologous signal sequence from
CD5 in place of that of wild-type HIV-1 Env. The proteolytic cleavage site
between gp120 and gp41 was altered, substituting serine residues for Arg
508 and Arg 511. In the JR-FL Env()712 and Env()808 glycopro-
teins, the Env cytoplasmic tail was modified by replacement of the codons
for Tyr 712 and Lys 808, respectively, with sequences encoding a
(Gly)2(His)6 tag and a (Gly)3(His)6 tag, respectively, followed immedi-
ately by a TAA stop codon. For control over Env expression, the JR-FL
Env()712 and Env()808 coding sequences were cloned immedi-
ately downstream of the tetracycline (Tet)-responsive element (TRE).
Our expression strategy further incorporated an internal ribosomal entry
site (IRES) and a contiguous puromycin (puro) T2A enhanced green flu-
orescent protein (EGFP) open reading frame (23) downstream of env
(TRE-env-IRES-puro.T2A.EGFP).
Exogenous membrane-anchored Env was produced by expression in
CHO cells. Briefly, vectors comprising the Env()712 and Env()808
sequences were packaged, pseudotyped with vesicular stomatitis virus
(VSV) G protein, and used to transduce CHO cells (Invitrogen) constitu-
tively expressing the reverse Tet transactivator (rtTA) (24). Transduced
cells were incubated for 24 h in a culture medium containing 1 g/ml of
doxycycline (DOX) and were then selected for 5 to 7 days in a medium
supplemented with puromycin (10 g/ml). High-producer clonal cell
lines were derived using a FACSAria cell sorter (BD Biosciences) to isolate
individual highly EGFP fluorescent cells. The integrity of the recombinant
Env()712 and Env()808 sequences in the clonal lines was con-
firmed by sequence analysis of PCR amplicons. Clonal cultures were
adapted for growth in a serum-free suspension culture medium
(CDM4CHO; Thermo Fisher, Waltham, MA). For the production of ex-
ogenous Env protein, cells were expanded in a suspension culture using a
14-liter New Brunswick BioFlo 310 fermentor (Eppendorf, Hauppauge,
NY) and were treated with 1 g/ml of DOX after reaching a volume of 10
liters and a density of 4  106 cells per ml. After 18 to 24 h of culture with
DOX, the cells were harvested by centrifugation, snap-frozen in a dry-ice–
ethanol bath, and cryostored at 80°C until analysis. The cell pellets were
homogenized in a homogenization buffer (250 mM sucrose, 10 mM Tris-
HCl [pH 7.4], and a cocktail of protease inhibitors [Roche Complete
tablets]). The plasma membranes were then extracted from the homoge-
nates by ultracentrifugation and sucrose gradient separation. The ex-
tracted crude plasma membrane pellet was collected and was solubilized
in a solubilization buffer containing 100 mM (NH4)2SO4, 20 mM Tris-
HCl (pH 8), 300 mM NaCl, 20 mM imidazole, 1% (wt/vol) Cymal-5
(Affymetrix), and a cocktail of protease inhibitors (Roche Complete tab-
lets). The membranes were solubilized by incubation at 4°C for 30 min on
a rocking platform. The suspension was ultracentrifuged for 30 min at
200,000  g and 4°C. The supernatant was collected and was mixed with
a small volume of preequilibrated Ni-nitrilotriacetic acid (NTA) beads
(Qiagen) for 8 to 12 h on a rocking platform at 4°C. The mixture was then
injected into a small column and was washed with a buffer containing 100
mM (NH4)2SO4, 20 mM Tris-HCl (pH 8), 1 M NaCl, 30 mM imidazole,
and 0.5% Cymal-5. The bead-filled column was eluted with a buffer con-
taining 100 mM (NH4)2SO4, 20 mM Tris-HCl (pH 7.4), 250 mM NaCl,
250 mM imidazole, and 0.5% Cymal-5. The eluted Env()712 or
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Env()808 glycoprotein solution was concentrated and was diluted in a
buffer containing 20 mM Tris-HCl (pH 7.4), 300 mM NaCl, and 0.01%
Cymal-6 for analysis of glycosylation profiles.
Expression and purification of soluble HIV-1 JR-FL gp140. The gene
encoding HIV-1 JR-FL soluble gp140CF, with a deletion of the gp120 –
gp41 cleavage site(C) and fusion domain (F), was codon-optimized by
converting the HIV-1 JR-FL Env amino acid sequences to nucleotide se-
quences employing the codon usage of highly expressed human house-
keeping genes (25). The codon-optimized env gene was synthesized de
novo (GenScript, Piscataway, NJ) and was cloned in the pcDNA3.1(	)/
hygromycin plasmid (Life Technologies, Carlsbad, CA), as described pre-
viously (32). The recombinant HIV-1 JR-FL soluble gp140CF glycopro-
tein was purified from serum-free culture supernatants of CHO cells
transiently transfected with the pcDNA3.1 plasmid expressing the soluble
gp140CF glycoprotein. Purification was achieved by using Galanthus
nivalis lectin-agarose beads (Vector Laboratories, Burlingame, CA), and
the purified protein was stored at 80°C until use. Galanthus nivalis lectin
exhibits a preference for (
1,3)-mannose residues and can bind the tri-
mannosyl core of high-mannose and processed glycans.
Deglycosylation of HIV-1 Env trimers. Samples containing 75 g of
the HIV-1 JR-FL Env glycoproteins were fully and partially deglycosylated
with PNGase F and Endo H, respectively. Full deglycosylation was per-
formed by incubating the Env samples with 1 l of PNGase F solution
(500,000 U/ml) for a week at 37°C and pH 8.0. For partial deglycosylation,
the pH of the sample solution was adjusted to 5.5 with 200 mM HCl,
followed by the addition of 2.5 l of Endo H (3 U/ml). After thorough
mixing, the reaction mixture was incubated for 48 h at 37°C. The pH of the
deglycosylated samples was adjusted to 8.0 with 300 mM NH4OH prior to
tryptic digestion. Deglycosylated samples were digested with trypsin as
described below.
Proteolytic digestion of HIV-1 Env trimers. HIV-1 JR-FL Env sam-
ples (75 g) at a concentration of 1 mg/ml were denatured with 6 M
urea in 100 mM Tris buffer (pH 8.0) and were fully reduced using 5 mM
TCEP at room temperature for 1 h. Following reduction, cysteine residues
were alkylated with 20 mM IAM at room temperature for another hour in
the dark. Excess IAM was quenched by adding DTT to a final concentra-
tion of 30 mM and incubating for 20 min at room temperature. The
reduced and alkylated samples were buffer exchanged and were concen-
trated using a 30,000 molecular weight cutoff (MWCO) filter (Millipore)
prior to protease digestion using trypsin and a combination of trypsin and
chymotrypsin. All protease digestions were performed according to the
manufacturer’s suggested protocols: digestion with trypsin was per-
formed with a 30:1 protein/enzyme ratio at 37°C for 18 h; chymotrypsin
digestion was performed with a 20:1 protein/enzyme ratio at 30°C for 10
h; and digestion with the combination of both proteases (a mixture of
trypsin and chymotrypsin) was performed using the same protein/en-
zyme ratio as that used for single-enzyme digestion, and the mixture was
incubated overnight at 37°C. The resulting HIV-1 glycoprotein digest was
either directly analyzed or stored at 20°C until further analysis. To en-
sure the reproducibility of the method, protein digestion was performed
at least three times on different days with samples obtained from the same
batch and analyzed with the same experimental procedure.
Chromatography and mass spectrometry. High-resolution LC-MS
experiments were performed using an linear trap quadrupole (LTQ) Or-
bitrap Velos Pro mass spectrometer (Thermo Scientific, San Jose, CA)
equipped with electron transfer dissociation (ETD) that is coupled to an
Acquity ultraperformance LC (UPLC) system (Waters, Milford, MA).
Mobile phases consisted of solvent A (99.9% deionized H2O plus 0.1%
formic acid) and solvent B (99.9% CH3CN plus 0.1% formic acid). Five
microliters of the sample (7 M) was injected onto a C18 PepMap 300
column (300 m inside diameter by 15 cm; 5 m particle size; 300 Å pore
size; Thermo Scientific Dionex) at a flow rate of 5 l/min. The following
CH3CN–H2O multistep gradient was used: 3% solvent B for 5 min, fol-
lowed by a linear increase to 40% solvent B in 50 min and then a linear
increase to 90% solvent B in 15 min. The column was held at 97% solvent
B for 10 min before reequilibration. A short wash and blank run were
performed between every two samples to ensure that there was no sample
carryover. All mass spectrometric analysis was performed in a data-de-
pendent mode as described below. The electrospray ionization (ESI)
source was operated under the following conditions: source voltage, 3.0
kV; capillary temperature, 260°C; S-lens value of 45 to 55%. Data were
collected in the positive-ion mode. The data-dependent acquisition
(DDA) mode was set up to sequentially and dynamically select the five
most intense ions in the survey scan in the mass range, 300 to 2,000 m/z,
for alternating collision-induced dissociation (CID) and ETD in the LTQ
linear ion trap using a normalized collision energy of 30% for CID and an
ion-ion reaction time of 100 to 150 ms for ETD. Full MS scans were
measured at a resolution (R) of 30,000 at m/z 400. Under these conditions,
the measured R (full width at half maximum [FWHM]) in the Orbitrap
mass analyzer is 20,000 at m/z 1,000 and 17,000 at m/z 1,500.
Glycopeptide identification. Data were analyzed using GlycoPep DB
(26), GlycoPep ID (27), and GlycoMod (28). Details of the compositional
analysis have been described previously (29–31). Briefly, compositional
analysis of glycopeptides with one glycosylation site was carried out by
first identifying the peptide portion from tandem MS (MS-MS) data. The
peptide portion was inferred manually or by GlycoPep DB from the Y1
ion, a glycosidic bond cleavage between the two N-acetylglucosamine res-
idues at the pentasaccharide core. Once the peptide sequence was deter-
mined, plausible glycopeptide compositions were obtained using the
high-resolution MS data and GlycoPep DB, and the putative glycan can-
didate was confirmed manually by identifying the Y1 ion and glycosidic
cleavages from the CID data. Peptide fragment ions from ETD spectra of
glycopeptides identified from a preceding CID scan were manually as-
sessed for peptide fragment ions by using ProteinProspector (http:
//prospector.ucsf.edu). Matched fragment ions within 0.5 Da of the theoret-
ical value were accepted. For glycopeptides with multiple glycosylation
sites, experimental masses of glycopeptide ions from the high-resolution
MS data were converted to singly charged masses and were submitted to
GlycoMod. This program calculates plausible glycopeptide compositions
from the set of experimental mass values entered by the user, compares
these mass values with theoretical mass values, and then generates a list of
plausible glycopeptide compositions within a specified mass error. Plau-
sible glycopeptide compositions in GlycoMod were deduced by providing
the mass of the singly charged glycopeptide ion and the enzyme, protein
sequence, cysteine modification, mass tolerance, and possible types of
glycans present in the glycopeptide. Plausible glycopeptide compositions
obtained from the analysis were manually confirmed and validated from
CID and ETD data.
Peptide identification. Deglycosylated peptides were identified by
searching raw data acquired on the LTQ Orbitrap Velos Pro mass spec-
trometer against a custom HIV database with 147 gp120/gp41 sequences,
obtained from the Los Alamos HIV sequence database (http://www.hiv
.lanl.gov/content/index), by using Mascot (version 2.5.0; Matrix Science,
London, United Kingdom). The peak list was extracted from raw files
using the MassMatrix conversion tool. Mascot generic format (MGF) files
were searched by specifying the following parameters: (i) enzyme, trypsin;
(ii) missed cleavage, 2; (iii) fixed modification, carbamidomethyl; (iv)
variable modification, methionine oxidation, carbamyl, HexNAc, and
dHexNAc; (v) peptide tolerance, 0.8 Da; and (vi) MS-MS tolerance, 0.4
Da. Peptides identified from the Mascot search were manually validated
from MS-MS data to ensure that major fragmentation ions (b and y ions)
were observed, especially for peptides generated from PNGase F-treated
samples that contain N-to-D conversions.
RESULTS
HIV-1 JR-FL envelope glycoproteins. Three HIV-1 Envs based
on the neutralization-resistant clade B primary isolate HIV-1 JR-
FL, including two detergent-solubilized, membrane-anchored
trimers and soluble gp140, were produced in CHO cells and were
used for this study. The membrane-anchored JR-FL Envs are des-
Glycosylation Profile of HIV-1 Env Trimers
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ignated Env()712 and Env()808, while the soluble gp140
Env is designated soluble gp140CF. According to the standard
numbering of the reference strain, HXB2, the Env()712 and
Env()808 membrane-anchored JR-FL Env trimer constructs
contain two serine substitutions at the proteolytic cleavage site
(residues 508 and 511) (32, 33). Amino acid residues 712 to 856
and 808 to 856 of the cytoplasmic tail were truncated for the
Env()712 glycoprotein and the Env()808 glycoprotein, re-
spectively, to improve Env expression. Both membrane-anchored
HIV-1 JR-FL Envs retain the complete ectodomain and the
membrane-spanning domain. The purified Env()712 and
Env()808 glycoproteins exhibited gel filtration profiles consis-
tent with that of a trimer (data not shown). Sequence modification
of the soluble HIV-1 JR-FL Env soluble gp140CF construct in-
cludes the removal of the proteolytic cleavage site (C; residues 510
to 511) and the fusion peptide of gp41 (F; residues 512 to 527) (29,
34, 35). In an effort to ensure that the differences in glycosylation
profiles were not due to sample preparation or to experimental
variations, the data presented in this study were obtained from
samples that were digested and analyzed at least three times using
the same batch. Batch-to-batch variation in glycosylation profiles
was evaluated using Env()712 produced from two different
batches.
Site-specific glycosylation analysis of HIV-1 JR-FL Envs. The
HIV-1 JR-FL Env contains 27 potential N-linked glycosylation
(PNG) sites, as shown in Fig. 1 (red). We have identified two
potential O-linked sites (purple) on the HIV-1 JR-FL Envs. The
O-linked modifications occur at threonines located near the
gp120 C terminus and the gp41 disulfide loop. The approach for
elucidating the glycosylation profiles at each potential N- and O-
linked site was based on an integrated glycopeptide-based mass
analysis workflow that included sample aliquots of the HIV-1
JR-FL Envs that were fully and partially deglycosylated prior to
proteolytic digestion (36, 37). Glycopeptides generated from in-
solution proteolytic digests of both untreated and glycosidase-
treated HIV-1 JR-FL Env samples were subsequently analyzed by
LC-MS and MS-MS using a combination of CID and ETD. Gly-
copeptide compositions were elucidated by the GlycoPep DB,
GlycoMod, and Mascot software analysis tools, as described in
Materials and Methods.
In silico trypsin digestion of HIV-1 JR-FL Env yields 17 pep-
tides containing the 27 potential N-linked and 2 potential
O-linked sites. The theoretical tryptic peptide map containing po-
tential N- and O-linked glycosylation sites includes 11 peptides
containing one potential glycosylation site, 4 peptides containing
two potential glycosylation sites, 2 peptides containing three po-
tential glycosylation sites, and 1 peptide containing five potential
glycosylation sites (Fig. 1). In an effort to achieve full glycosylation
coverage and to characterize the glycan motif at each site, we inte-
grated a two-protease digestion strategy, as decribed in Materials and
Methods, in addition to using trypsin alone. We used chymotrypsin
to complement trypsin to access potential glycosylation sites in tryp-
tic peptides bearing multiple sites. With the combination of tryp-
sin and chymotrypsin, we obtained full glycosylation coverage
representing all 27 potential N-linked sites and expanded the site-
specific glycan characterization of Env regions that contained
tryptic peptides bearing multiple glycosylation sites; this was par-
ticularly important for the tryptic peptide bearing five potential
glycosylation sites located in the gp120 V4 region. In addition, the
use of trypsin-chymotrypsin digestion provided secondary valida-
tion of many of the identifications made on the basis of the diges-
tion with trypsin alone, due to the redundant coverage of the same
regions of Env.
The glycan profiles of the glycopeptides generated from the
proteolytic digests of the HIV-1 JR-FL Envs were deduced from
both MS and MS-MS data obtained from a glycopeptide-rich re-
gion extracted from a time segment of the total-ion chromato-
gram (TIC). As an example, putative glycopeptides in the high-
resolution mass spectra extracted from a segment of the TIC were
identified from cluster peaks whose mass difference corresponds
to the masses of monosaccharide units (hexose, HexNAc, fucose)
(Fig. 2A). The glycan and peptide portions of a glycopeptide peak
in question were elucidated and verified from fragment ion infor-
mation obtained in CID and ETD data. Figure 2B and C show
representative CID and ETD data used to assign the glycopeptide
peak at m/z 1,216 (3	). From the glycosidic bond cleavage ob-
served in the CID spectrum, the glycan component of the peak
consists of 10 hexose and 2 HexNAc units (Fig. 2B). The peptide
portion of this high-mannose glycopeptide was inferred from the
Y1 ion observed at m/z 912.2 (2	). This Y1 ion corresponds to the
peptide LDVVPIDNN186N187TSYR, located in the gp120 V2 re-
gion. Additional fragment information obtained from the peptide
backbone cleavages observed in the ETD spectrum further con-
firms the peptide sequence and site utilization (Fig. 2C). Using
CID and ETD data acquired from this glycopeptide-rich region
and the software analysis tool GlycoPep DB (26), three sets of
glycopeptides were identified in the high-resolution mass spec-
trum shown in Fig. 2A. Overall, full coverage for all 27 potential
N-linked glycosylation sites was obtained, and O-glycosylation
profiles on T499 and T606 were elucidated on all HIV-1 JR-FL Env
samples.
Glycan heterogeneity of HIV-1 JR-FL Envs. All three HIV-1
JR-FL Envs displayed extensive site-to-site glycan heterogeneity.
The number of glycoforms identified ranges from 3 to 79 at each
potential N-glycosylation site, and at least 3 O-linked glycans per
site were identified (see Tables S1, S2, and S3 in the supplemental
material). As an example, the glycan heterogeneity observed for a
glycopeptide containing three potential glycosylation sites is illus-
trated in Fig. 3. Figure 3A to D show the representative ETD and
CID data used to identify the different glycans observed for the
tryptic glycopeptide containing the peptide portion
LICTT606AVPWN611ASWSN625K, two potential N-linked glyco-
sylation sites at N611 and N625, and one O-linked glycosylation
site at T606. Tandem MS analyses show that both N-linked sites at
N611 and N625 were modified with high-mannose glycans when
fully glycosylated (Fig. 3A) and with complex-type glycan when
partially glycosylated (Fig. 3B). ETD analysis of the quadruply
charged glycopeptide at m/z 1,160 shown in Fig. 3B provided suf-
ficient fragment ion information to establish that N611 was mod-
ified with a fucosylated and sialylated tetra-antennary complex-
type glycan.
In addition to the N-linked glycans, we identified an O-linked
modification at T606 on the same glycopeptide for the first time.
The combination of two sets of glycans on the same glycopeptide
poses a unique challenge in the interpretation of MS data due to
the proximity of the O-glycosylation to the N-linked sites and the
smaller size of O-linked glycans. To address this challenge, Env
samples can be fully deglycosylated with PNGase F to remove the
N-linked modifications, followed by trypsin digestion, or directly
digested with the combination of trypsin-chymotrypsin. LC-MS
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and MS-MS analysis of tryptic digests of PNGase F-treated Env
samples indeed confirmed the identification of O-linked modified
threonine. Glycosidic and peptide backbone cleavages from the
representative CID (Fig. 3C) and ETD (Fig. 3D) spectra, respec-
tively, established that T606 on the N-deglycosylated peptide was
modified with core-1 type O-linked glycan. This assignment was
further confirmed with Env samples generated from trypsin-chymo-
trypsin digests, in which O-linked modifications in the trypsin-chy-
motrypsin-derived peptides, ICTT606AVPW and LICTT606AVPW,
were identified. Overall, we identified two O-linked modified threo-
nine residues, located near the gp120 C terminus and the gp41 disul-
fide loop, in the HIV-1 JR-FL membrane-anchored Env trimers and
soluble gp140CF glycoprotein.
Comparison of the glycan profile among HIV-1 JR-FL Envs.
A total of 500 distinct glycans representing the 27 N-linked and
2 O-linked potential glycosylation sites per HIV-1 JR-FL Env sam-
ple were identified, as reported fully in Tables S1, S2, and S3 in the
supplemental material. Each glycopeptide containing N-linked
site displayed extensive glycan heterogeneity, including a single
HexNAc, high-mannose glycans, hybrid-type glycans, and com-
plex-type glycans consisting of a mixture of bi-, tri-, and tetra-
antennary structures with or without fucosylation and with vary-
ing degrees of sialylation. The glycopeptides with O-linked sites
were modified with core-1 and core-2 type O-linked glycans. The
glycan profile for each HIV-1 JR-FL Env was determined by sort-
ing the glycan compositions elucidated for each glycopeptide into
FIG 1 Protein sequences of the HIV-1 JR-FL membrane-anchored Envs [Env()712 and Env()808] and soluble gp140CF, showing locations of
conserved (C1 to C5) (green lines) and variable (V1 to V5) (blue lines) regions, potential N- and O-linked glycosylation sites (red and purple numbers,
respectively), and the tryptic peptide map (orange lines beneath sequences). Sequence positions were standardized using the HIV-1 reference strain HXB2.
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two groups, high-mannose and processed glycans (hybrid- and
complex-type glycans), using the criteria employed in our previ-
ous studies (29, 31). The glycan profile for each glycopeptide con-
taining a single or multiple glycosylation site(s) is represented in
Fig. 4 by a pair of bars labeled with the sequence position. The
overall glycan profiles of (i) two membrane-anchored HIV-1
JR-FL Env()712 glycoproteins purified on different days (Fig.
4A and B), (ii) the membrane-anchored HIV-1 JR-FL trimer
Env()808 (Fig. 4C), and (iii) the HIV-1 JR-FL soluble
gp140CF glycoprotein (Fig. 4D) are shown. The degrees of sia-
lylation of these Env variants are compared in Fig. 5. The percent-
age of sialylation for each glycopeptide was determined by calcu-
lating the ratio of the sum of the sialylated glycopeptides to the
total number of processed glycans and multiplying by 100. It is
evident that each unique HIV-1 JR-FL Env variant displays a dis-
tinct glycan profile. The glycan variability observed for the HIV-1
JR-FL Env glycoproteins and shown in the bar graphs in Fig. 4 and
5 is described in the following sections.
Glycan profiles of membrane-anchored HIV-1 JR-FL trimers
from two different batches. As a measure of the reproducibility of
the glycosylation profiles in terms of glycan composition for each
glycopeptide, the glycan profiles of preparations of the mem-
brane-anchored HIV-1 JR-FL Env Env()712, produced from
two different batches at two different concentrations, were ex-
amined and compared. The bar graphs showing the N-linked
glycan profile of the membrane-anchored HIV-1 JR-FL Env
Env()712 produced from each batch indicate very good re-
producibility (Fig. 4A and B). Close examination of the O-linked
FIG 2 High-resolution and tandem MS data of membrane-anchored Env()712. (A) Representative high-resolution MS data of a tryptic digest of the CHO
cell-derived membrane-anchored Env()712 glycoprotein. The mass spectrum averaged within 26.18 to 27.47 min shows the elution of four glycopeptide
species. Starbursts in the MS data denote glycopeptide peaks. The glycan composition of each glycopeptide peak observed in the mass spectra was verified from
CID and ETD data. (B) CID data of a high-mannose glycopeptide with the peptide portion, LDVVPIDNN186N187TSYR, showing glycosidic cleavages. (C) ETD
data of the same glycopeptide showing the peptide backbone cleavages.
Go et al.
8250 jvi.asm.org August 2015 Volume 89 Number 16Journal of Virology
 on D
ecem









glycans reveals no difference in the number or type of O-linked
glycans detected in the two batches (Table 1). Additionally, the
sialylation of these two proteins was remarkably consistent, as
shown in Fig. 5A. These results suggest that the differential glycan
profiles reported in this study reflect the glycan variability between
distinct HIV-1 JR-FL Envs and are not related to sample process-
ing or the batch of the proteins used for analysis.
Glycan profiles of membrane-anchored HIV-1 JR-FL trimers
with different cytoplasmic tail lengths. Having established the
reproducibility of our measurements, we compared the N- and
O-linked glycan profiles of membrane-anchored trimers differing
in the lengths of their cytoplasmic tails. The Env()712 glyco-
protein lacks the cytoplasmic tail, whereas the Env()808 gly-
coprotein contains all the elements of the cytoplasmic tail that
have been reported to contribute to the conformation of the Env
ectodomain and to modulate Env transitions to fusion-active
states (25, 38, 39). With regard to N-glycosylation, Env()712
and Env()808 displayed similar ranges of N-linked glycans
(see Tables S1 and S2 in the supplemental material). The overall
N-glycan profiles generated from 21 glycopeptides bearing the 27
N-linked sites on both Env()712 and Env()808 are shown
in Fig. 4A and C. Notable features of the data are as follows. First,
the N-glycan profiles of both Env()712 and Env()808 con-
sist of high-mannose and processed glycans. The high-mannose
structures for both Env()712 and Env()808 contain as
many as 12 hexose units, whereas the processed glycans are
predominantly complex-type structures. Second, six glycopep-
tides bearing seven N-linked sites (N156, N334, N386, N392,
N397, N403, and N448) in both Env()712 and Env()808
are populated exclusively with high-mannose glycans. While
Env()712 has one more site with exclusively high-mannose
glycans than Env()808 (N262), Env()808 has a higher con-
tent of high-mannose glycans overall than Env()712. Third,
the complex-type glycans consist mostly of multiantennary com-
plex-type glycan structures that display variability in sialic acid
content. The bar graph in Fig. 5B depicting the difference in the
degree of sialylation between the two proteins shows that
Env()712 has a higher sialic acid content than Env()808.
With respect to O-linked glycosylation, the two potential O-
linked sites at T499 and T606 were both modified in the mem-
brane-anchored trimers. All O-linked sites utilized in both
Env()712 and Env()808 were modified with a simple set of
core-1 type structures ranging from a single HexNAc to disialy-
lated O-linked species, as shown in Table 1.
FIG 3 Tandem MS data of a glycopeptide in the gp41 region of HIV-1 JR-FL Env. Shown are representative tandem MS data of the glycopeptide with the peptide
portion, LICTT606AVPWN611SSWSN616K, illustrating the different types of glycans attached on each site. (A) ETD data of the glycopeptide with high-mannose
glycans. (B) ETD data of the same glycopeptide with complex-type glycan. (C and D) CID and ETD data of the deglycosylated glycopeptide showing an O-linked
glycan attached at T606.
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Glycan profiles of membrane-anchored HIV-1 JR-FL Env
trimers compared with that of the HIV-1 JR-FL soluble
gp140CF glycoprotein. Next, we examined whether the form,
i.e., membrane anchored or soluble, of the HIV-1 JR-FL Env in-
fluences N- and O-glycan profiles. Figure 4D shows a bar graph
reflecting the overall N-glycan profile of the HIV-1 JR-FL soluble
gp140CF expressed in CHO cells. The 27 potential N-glycosyla-
tion sites of this soluble gp140 glycoprotein were populated pre-
dominantly with processed glycans consisting of hybrid-type gly-
cans and a diverse mixture of bi-, tri-, tetra-, and penta-antennary
complex-type glycan structures with or without fucosylation and
with various degrees of sialylation (see Table S3 in the supple-
mental material). This profile is essentially identical to a profile
reported previously for the HIV-1 JR-FL soluble gp140CF
glycoprotein expressed in 293T cells (29). The glycan profile of
the soluble gp140CF glycoprotein is completely different
from the N-glycan profiles of the membrane-anchored trimers,
Env()712 and Env()808, where 9 of the 21 glycopeptides
are populated predominantly with high-mannose glycans. Glyco-
sylation sites with mostly processed glycans in the soluble
gp140CF all contained sialic acid (Fig. 5C). When these sites
were compared among gp140CF, Env()712, and Env()
808, site-to-site variation in the degree of sialylation was ob-
served; however, the sialic acid content of the secreted gp140CF
protein most resembled that of Env()712.
The membrane-anchored and soluble JR-FL Envs displayed
similar core-1 type O-glycan profiles at site T499, as shown in
Table 1. Four core-1 type O-glycans were observed at T499 for all
of the HIV-1 JR-FL Envs. The O-glycan profiles displayed signif-
icant differences at gp41 site T606, located close to two potential
N-linked glycosylation sites. At T606, a total of eight O-glycans
consisting of core-1 and core-2 type O-glycans were identified
in the soluble gp140CF glycoprotein, whereas a simple set of
core-1 type O-glycans was identified in both Env()712 and
Env()808 (Table 1).
Site occupancy of HIV-1 JR-FL Envs. As with the HIV-1 Envs
we have analyzed previously (29, 31, 36, 37), not all potential
glycosylation sites in the HIV-1 JR-FL Envs are fully utilized. The
extent of glycosylation was determined from the LC-MS and
MS-MS analysis of Endo H- and PNGase F-treated HIV-1 JR-FL
Envs, as described previously (36, 37). Data acquired from MS
analysis were used to search a custom HIV-1 database by using
Mascot as described in Materials and Methods. Table 2 shows the
extents of glycosylation for the 27 potential N-linked and 2 O-
linked glycosylation sites of HIV-1 JR-FL soluble gp140CF,
Env()808, and the two different batches of Env()712. In
agreement with the results obtained from the analysis of glycan
profiles, the results from the two different batches of the
Env()712 glycoprotein clearly show that differences in site oc-
cupancy were not due to variation between batches. A striking
observation is that the extent of glycosylation can be affected by
the presence of Env cytoplasmic tail sequences. Env()808,
which retains a cytoplasmic tail and is the longest of the three
glycoproteins analyzed, has more fully utilized N-linked sites than
Env()712, which is identical to Env()808 except for the
absence of the cytoplasmic tail. The least glycosylated protein,
soluble gp140CF, is not membrane anchored and lacks a trans-
membrane region as well as a cytoplasmic tail.
DISCUSSION
The continuing effort to produce Envs that closely mimic the na-
tive functional Env spike has driven the development of next-
FIG 4 Glycan profiles of HIV-1 JR-FL Env glycoproteins. (A to C) Bar graphs show the glycan profile at each identified glycosylation site of the HIV-1 JR-FL
membrane-anchored Env Env()712 (A), a different batch of Env()712 (B), and Env()808 (C). (D) Glycan profile of the soluble gp140CF glycopro-
tein. Glycans were broadly categorized into two classes, high-mannose (red bars) and processed (blue bars) glycans, and the glycan composition of each
glycopeptide is expressed as a percentage. Glycan compositions at sites marked with a star were determined from Endo H-treated samples.
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generation Env-based vaccines. To date, different forms of Env,
including membrane-anchored trimers, a number of iterations of
the soluble versions of gp140 glycoproteins, and Envs from viral
preparations, are being used in immunogenicity, biophysical, and
structural studies to identify potential Env candidates that would
induce a broad and potent neutralizing antibody response
against HIV-1 (21, 32, 33, 35, 40–44). Given that the extensive
glycosylation of the Envs is one of the important correlates of
Env immunogenicity and antigenicity, it is crucial to determine
the glycosylation profiles of native HIV-1 Envs and to identify
the glycosylation motifs that are immunologically significant.
In this study, MS-based glycosylation analysis was used to ad-
dress whether Env glycosylation is dependent on the Env form,
i.e., membrane anchored or soluble. We characterized and iden-
tified the differences between the N- and O-linked glycosylation
profiles of two membrane-anchored HIV-1 JR-FL Env trimers,
Env()712 and Env()808, and that of the soluble version
of HIV-1 JR-FL Env, gp140CF. Clearly, Env()712 and
Env()808 displayed N- and O-glycosylation profiles distinct
from that of soluble gp140CF. Specifically, both Env()712
and Env()808 have more N-linked sites populated with high-
mannose glycans, which include high-mannose structures bearing
10 to 12 hexoses. When Env is expressed in a more truncated,
soluble form, the glycans may be more accessible to glycan-pro-
cessing enzymes, resulting in a more heavily processed glycosyla-
tion profile. These results indicate that glycans of the soluble
gp140CF oligomer do not closely mimic those of membrane-
bound JR-FL Env, since they are processed differently in the en-
doplasmic reticulum (ER) and Golgi apparatus. Our observation
that membrane-associated Envs display significantly more high-
mannose glycans than a soluble Env is consistent with previous
studies of Env isolated from virions, which exhibited a preponder-
ance of high-mannose carbohydrates (21, 22, 45). The fact that
Env complexes on the cell surface serve as the direct source of
virion Env spikes explains this consistency in glycosylation pro-
files. Because proteolytic cleavage is a very late event in Env bio-
synthesis, the glycosylation profile of our cleavage-negative mem-
brane Envs is expected to resemble closely those of the mature cell
surface and virion Envs.
Our studies extend previous analyses and provide new insight
FIG 5 Degrees of sialylation of HIV-1 JR-FL Env glycoproteins. Bar graphs
show comparisons of the degrees of sialylation of preparations of membrane-
anchored Env()712 glycoprotein produced on different days (A), mem-
brane-anchored Env()712 and Env()808 glycoproteins (B), and mem-
brane-anchored Env()712 and Env()808 and soluble gp140CF (C).
The percentage of sialylation for each site was determined by the sum of sialy-
lated glycopeptides divided by the total number of processed glycopeptides,
multiplied by 100.




Env()808 Soluble gp140CFPrep 1 Prep 2
IEPLGVAPT499KAK HexNAc ✓ ✓ ✓ ✓
[Hex]1[HexNAc]1 ✓ ✓ ✓ ✓
[Hex]1[HexNAc]1[NeuAc]1 ✓ ✓ ✓ ✓
[Hex]1[HexNAc]1[NeuAc]2 ✓ ✓ ✓ ✓
LICTT606AVPWD611ASWSD625K or
ICTT606AVPW/LICTT606AVPW
HexNAc ✓ ✓ ✓ ✓
[Hex]1[HexNAc]1 ND ND ND ✓
[Hex]1[NeuAc]1 ND ND ND ✓
[Hex]1[HexNAc]1[NeuAc]1 ✓ ✓ ✓ ✓
[Hex]1[HexNAc]1[NeuAc]2 ✓ ✓ ✓ ✓
[Hex]1[HexNAc]2[NeuAc]1 ND ND ND ✓
[Hex]2[HexNAc]2[NeuAc]1 ND ND ND ✓
[Hex]2[HexNAc]2[NeuAc]2 ND ND ND ✓
a ✓, the O-glycan was observed; ND, not detected.
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into membrane-anchored glycosylation profiles of Env because
the glycoform profile can be elucidated at each glycosylation site.
A benefit of glycopeptide analysis on these proteins, compared to
glycan analyses, is the ability to track minority glycoform popula-
tions. When aggregate glycan analysis was conducted on virion
Env, sialylated glycoforms were not detected (21, 22). Glycopep-
tide analysis provides increased depth in glycoform profiling be-
cause low-abundance glycoforms, which are present at only a few
glycosylation sites, can be detected, even when high-mannose gly-
cans dominate most of the glycosylation sites. Glycopeptide anal-
ysis of Env()712 and Env()808 shows multiple glycosyla-
tion sites bearing processed glycans that contain significant levels
of sialic acid. The presence of sialylated glycans can have a pro-
found effect on Env antigenicity and immunogenicity, since sialic
acids are known to modulate the host immune response, acting as
recognition elements for lectins and as biological masks (46, 47).
Additionally, some broadly neutralizing antibodies recognize an
epitope that includes sialic acid at N156 (15).
Comparison of Env sialic acid contents in this study showed
that Env()808 contained less sialic acid than Env()712. Ap-
parently, as has been suggested by other studies (25, 38, 39), the
cytoplasmic tail can influence the conformation of the HIV-1 Env
ectodomain, resulting in differences in the processing of high-
mannose glycans in the Golgi apparatus. This difference could be
significant for vaccine developers, because a low sialic content on
gp120 has been shown to improve immunogenicity (12). Both
membrane-bound Env trimers displayed less sialic acid than the
soluble gp140CF glycoprotein. This trend suggests that perhaps
membrane-anchored trimers are less sialylated than soluble, trun-
cated versions of the same protein.
While global differences in the glycan processing of these Env
variants were observed, these data sets are also useful for compar-
ing glycosylation profiles at specific glycosylation sites of interest,
such as those that interact with broadly neutralizing antibodies.
For example, recent work by Amin et al. (15) and others (48) has
shown that the broadly neutralizing antibody PG16 prefers a high-
mannose glycan at N160 and a sialylated glycoform at N156. This
antibody is known to prefer trimeric forms of Env, but it does not
bind to trimeric HIV-1 JR-FL because of a glutamic acid residue at
position 168 in the gp120 V2 region (19). The glycosylation anal-
ysis data presented here help to explain why the binding of these
antibodies is not optimal, even when residue 168 in the JR-FL Env
is altered (32). The HIV-1 JR-FL membrane Envs contain a high-
mannose (nonsialylated) glycosylation site at N156, and N160 is
modified by a large number of processed glycans. Thus, even
though the HIV-1 JR-FL Env, like other cell surface HIV-1 Envs,
contains predominantly high-mannose glycans, the glycosylation
site-specific data show that these high-mannose glycans are not
universally present across all the glycosylation sites. The processed
glycans present at N160 likely reduce the levels of Env-binding
antibodies such as PG16, which prefer a high-mannose glycan at
this site.
In addition to studying the N-linked glycoforms on these Envs,
we identified two O-linked modifications on threonine residues
TABLE 2 Glycosylation site occupancy
Type of glycosylation and peptide
No. of PNG
sites




gp140CFPrep 1 Prep 2
N-Linked glycosylation
AYDTEVHNVWATHACVPTDPNPQEVVLEN88VTEHFNMWK 1 0 and 1 0 and 1 1 0 and 1
DVN135ATN138TTN141DSEGTMER 3 0, 1, and 2 0, 1, and 2 1 and 2 0, 1, and 2
N156CSF/GEIK N156CSF 1 0 and 1 0 and 1 0 and 1 0 and 1
N160ITTSIR/N160ITTSIRDEVQK 1 0 and 1 0 and 1 0 and 1 0 and 1
LDVVPIDNN186N187TSYR/LDVVPIDNN186N187TSY 2 0 and 1 0 and 1 0 and 1 0 and 1
N241VSTVQCTH/N241VSTVQCTHGIR 1 0 and 1 0 and 1 0 and 1 0 and 1
LLN262GSLAEEEVVIR/GIRPVVSTQLLLN262GSLAEEEVVIR 1 0 and 1 0 and 1 0 and 1 0 and 1
SDN276FTNNAK 1 0 and 1 0 and 1 1 0 and 1
ESVEIN295CTRPNN301NTR 2 0, 1, and 2 0, 1, and 2 1 and 2 1 and 2
QAHCN334ISR 1 0 and 1 0 and 1 1 0 and 1
WN339DTLK 1 0 and 1 0 and 1 0 and 1 0 and 1
EQFEN356K/LREQFEN356K 1 0 and 1 0 and 1 0 and 1 0 and 1
TIVFN362HSSGGDPEIVMH/TIVFN362H/N362HSSGGDPEIVMH 1 0 and 1 0 and 1 0 and 1 0 and 1
CN386STQLF/Y CN386STQLF 1 1 1 1 1
N392STW/F N392STW 1 1 1 1 1
NN397NTEGSN403NTEGNTITLPCR 2 2 2 2 0, 1, and 2
CSSN448ITGLLLTR/CSSN448ITGL 1 0 and 1 0 and 1 0 and 1 0 and 1
DGGINEN462GTEIFRPGGGDMR/DGGINEN462GTEIF 1 0 and 1 0 and 1 0 and 1 0 and 1
LICTTAVPWN611ASWSN616K 2 0, 1, and 2 0, 1, and 2 1 and 2 0, 1, and 2
IWNN625MTWMEWER 1 0 and 1 0 and 1 1 0 and 1
EIDN637YTSEIYTLIEESQNQQEK 1 0 and 1 0 and 1 1 0 and 1
Total 27 5–25 5–25 13–25 4–25
O-Linked glycosylation
IEPLGVAPT499KAK/IEPLGVAPT499K 1 0 and 1 0 and 1 0 and 1 0 and 1
LICTT606AVPWD611ASWSD616K/LICTT606AVPW/ICTT606AVPW 1 0 and 1 0 and 1 0 and 1 0 and 1
Total 2 0–2 0–2 0–2 0–2
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near the gp120 C terminus (T499) and the gp41 disulfide loop
(T606). The O-glycan at T499 is a common modification observed
in HIV-1 gp120 and gp140 Env glycoproteins analyzed previously
(37, 49, 50), whereas the O-linked modification on T606 was ob-
served for the first time in this study. Although the addition of
O-linked glycans is not absolutely required for the receptor-bind-
ing and membrane-fusing functions of HIV-1 Env (51), the very
high level of conservation of T606 among primate immunodefi-
ciency viruses (52) supports a potentially important role, perhaps
in immune evasion, for this O-glycan. For example, the presence
of this newly identified glycoform may impact the binding of an-
tibodies to the gp41 subunit of Env. Prior studies have shown that
when the N-linked glycans adjacent to this site, at N611 and N616,
are removed, the recognition of gp140 by two neutralizing anti-
bodies against the gp41 membrane-proximal external region
(MPER), 2F5 and 4E10, increases (53). While it is not known at
this time whether this newly identified O-linked glycan impacts
the binding of anti-MPER antibodies, structural studies of this
region and vaccine design strategies that target MPER epitopes
should account for this newly discovered feature of Env.
Because O-linked glycans are added late in glycoprotein bio-
synthesis, in the Golgi apparatus (54, 55), our observation that
O-linked glycans are added to T499 and T606 indicates that these
amino acid residues are exposed on the uncleaved membrane-
anchored and soluble HIV-1 JR-FL Env trimers. In a recently pub-
lished crystal structure of a soluble gp140 SOSIP.664 trimer from
HIV-1 BG505 (56), T499 is solvent exposed, but T606 is not. Thus,
the structures of the membrane and soluble HIV-1 JR-FL Env
trimers that we studied here must differ from that of the soluble
gp140 SOSIP.664 glycoprotein, at least in the vicinity of T606 in
gp41. Insights into the differences between native HIV-1 Env
trimers and glycoproteins such as soluble gp140 SOSIP.664 that
are being considered for use as immunogens may be helpful in
improving vaccine candidates.
A common glycosylation feature of the recombinant soluble
HIV-1 Envs we have analyzed to date is that a given glycosylation
site may be fully occupied, partially occupied, or not utilized at all
(29, 31, 36, 37, 57). Such variability in glycosylation site utilization
can directly influence the immunogenicity and antigenicity of
Envs. Indeed studies have shown that the absence and/or removal
of glycans increases antibody neutralization sensitivities (58–62).
We have demonstrated recently that soluble transmitted/founder
HIV-1 soluble gp140s expressed in different cell lines exhibit rel-
atively similar site utilization (37). In this study, we identified the
length of the cytoplasmic tail as a variable that can influence gly-
cosylation site occupancy. The two membrane-anchored HIV-1
JR-FL Envs with different C termini show significant differences in
their degrees of site occupancy. There are twice as many fully
utilized sites in CHO-derived Env()808 than in Env()712.
In contrast, Env()712 and the soluble gp140CF display sim-
ilar levels of glycosylation site utilization. Env()808 contains
almost 100 amino acids in the cytoplasmic tail that are not present
in the Env()712 or soluble gp140CF glycoprotein. It is not
clear at this point how this longer protein sequence influences
glycosylation site occupancy in the Env ectodomain, since the N-
terminal glycosylation sites can potentially be occupied prior to
translation of the C-terminal region. However, for a heavily gly-
cosylated protein such as Env, the additional time on the ribosome
associated with translation of a longer protein may allow more
complete engagement of all the sequons by the glycosylation ma-
chinery. More investigation into this issue is warranted. Whatever
the explanation, the trend we observe is an interesting and poten-
tially significant one: the Env that is most similar (in terms of
sequence) to native Env, Env()808, shows a significantly
higher degree of occupied glycosylation sites than more-truncated
versions of the same protein.
Finally, various attempts have been made to use kifunensine or
production in GnT1-negative cells to give soluble gp140 glycopro-
teins a glycan profile richer in mannose residues and lacking com-
plex carbohydrates. These approaches can restore some epitopes
involving high-mannose glycans on gp120. However, our results
suggest that naturally produced HIV-1 Env has a mixture of high-
mannose and processed carbohydrates that is highly site depen-
dent. This native glycosylation profile cannot be reproduced on
the soluble gp140 glycoproteins simply by inhibition of a particu-
lar glycosidase. Immunogens that derive from the membrane-an-
chored Envs should more closely mimic the glycan profile found
on infectious virions.
In conclusion, we evaluated and compared the glycosylation
profiles of membrane-anchored and soluble Envs derived from
the primary, neutralization-resistant HIV-1 JR-FL isolate using
CID/ETD-based glycopeptide analysis. Using this approach, we
achieved full glycosylation coverage of all 27 potential N-glycosy-
lation sites and characterized the O-linked glycosylation profiles
of Envs of different lengths. In general, the HIV-1 JR-FL Envs
analyzed in this study displayed distinct N- and O-glycosylation
profiles with extensive glycan heterogeneity at any given site. The
N-linked glycosylation profiles for different JR-FL Env forms dif-
fered considerably, particularly between membrane-anchored
Envs and soluble gp140. Specifically, the membrane-anchored
Envs, Env()712 and Env()808, contained more high-man-
nose glycans than the soluble gp140CF: the high proportion of
processed glycans on the soluble gp140 is consistent with prior
glycan-based analyses of similar proteins (21, 22). We also deter-
mined that Env()712 and Env()808 exhibited some spe-
cific differences in their N-glycosylation profiles. Relative to
Env()712, Env()808 has higher site occupancy, more sites
with high-mannose glycans, and a lower sialic acid content, sug-
gesting that the cytoplasmic tail can influence Env glycosylation.
We identified two O-linked glycosylation sites, one involving
T606 in the gp41 subunit that has not been previously described.
In general, site-to-site variation in O-linked modification was ob-
served for the three Envs. Defining the differences in N- and O-
linked glycosylation features across Env forms could provide crit-
ical information needed to understand the immunogenicity and
antigenicity of Env vaccine candidates. It will also be of interest to
determine whether any differences in the Env glycosylation profile
dependent on the virus-producing cell influence the biological
properties of HIV-1. More studies on additional Env sequences
will be necessary to understand the range of differences in glycan
type and occupancy associated with diverse strains of HIV-1 rep-
licating in various host cell types.
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